Nova Consumer Group JSC

Nova Consumer Group JSC has a debt-to-equity ratio of 0.75, indicating a moderate level of leverage, and a current ratio of 1.24, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -61,285,179,030 VND, which raises concerns about its ability to fund operations from core business activities.

The company's profitability is weak, with a return on equity of -1.31% and a return on assets of -0.64%, both significantly below the industry median for pharmaceutical companies. These metrics suggest that the company is not generating returns that meet the expectations of its shareholders or effectively utilizing its assets to generate profit.

Nova Consumer Group JSC's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases the company's exposure to market-specific risks and could limit its growth potential in new regions.

The company's revenue growth is expected to remain flat in the current fiscal year, with no significant improvement projected for the next fiscal year. This is consistent with the company's recent financial performance, which has shown declining profitability and negative operating cash flow.

The company faces several risk factors, including liquidity concerns due to its negative net cash position after subtracting total debt. While the risk of dilution is currently low, the company's financial structure and negative cash flow could necessitate future equity or debt financing, which may lead to dilution of existing shareholders' equity.

There are no recent events or filings disclosed in the latest financial data that would indicate significant changes in the company's operations or strategic direction. The absence of recent events suggests a stable but stagnant business environment for the company.

Net income surged 132.9% year-over-year to 193 billion VND, signaling a strong operational recovery.

Free cash flow increased 73.3% to 288 billion VND, demonstrating improved liquidity generation capabilities.

Long-term debt decreased to 1.2 trillion VND, reflecting a deliberate deleveraging strategy over recent periods.

Cash conversion ratio of 2.48 exceeds the pharmaceutical cohort median of 0.95 significantly.

Revenue grew 6.5% year-over-year, indicating modest top-line expansion despite broader market challenges.

Net margin of -2.5% remains well below the pharmaceutical cohort median of 3.9%.

Debt-to-equity ratio of 0.75 is significantly higher than the cohort median of 0.18.

The company faces high credit risk, posing potential challenges for future financing and stability.

Four-year net income CAGR of -10.4% reveals a history of volatile and declining profitability.